Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
暂无分享,去创建一个
M. Buyse | N. Robert | M. Gnant | H. Iwata | P. Tassone | C. Barrios | G. von Minckwitz | N. Masuda | S. Chia | F. Holmes | E. Gokmen | B. Moy | V. Harvey | S. Delaloge | J. Mansi | Miguel Martín | B. Ejlertsen | K. Petráková | N. Iannotti | A. Chan | Y. Ye | B. Yao | I. Gore | T. Silovski | G. Rodriguez | R. Bryce | G. Harker | A. Wong | Á. G. Zotano | John A. Smith | A. Chan